Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Runs Out Of Kallman Syndrome Treatments As Makers Drop Drugs

This article was originally published in PharmAsia News

Executive Summary

China's hospitals report a shortage of key hormones for treating cases of Kallman Syndrome, which often delays puberty and affects the sense of smell.

You may also be interested in...



Pfizer Chief Calls Patent Pool ‘Nonsense’, Fears Tussle Over Vaccine

Pharma will oppose a patent pool, but the world still needs a way to guarantee fair access to COVID-19 vaccines.

Sanofi Vaccines Chief Loew To Be Ipsen CEO

Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.

Pipeline Watch: Phase III Readouts In Eosinophilic Esophagitis, Myasthenia Gravis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel